[1]刘 筠.异环磷酰胺与依托泊苷联合治疗 复发卵巢癌的临床效果[J].医学信息,2019,32(13):143-144.[doi:10.3969/j.issn.1006-1959.2019.13.044]
　LIU Jun.Clinical Effect of Combination of Ifosfamide and Etoposide inTreatment of Recurrent Ovarian Cancer[J].Journal of Medical Information,2019,32(13):143-144.[doi:10.3969/j.issn.1006-1959.2019.13.044]
点击复制

异环磷酰胺与依托泊苷联合治疗 复发卵巢癌的临床效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年13期
页码:
143-144
栏目:
药物与临床
出版日期:
2019-07-01

文章信息/Info

Title:
Clinical Effect of Combination of Ifosfamide and Etoposide in Treatment of Recurrent Ovarian Cancer
文章编号:
1006-1959（2019）13-0143-02
作者:
刘 筠
天津市中心妇产科医院科室医政科，天津 300100
Author(s):
LIU Jun
Department of Medical Affairs,Tianjin Central Hospital of Obstetrics and Gynecology,Tianjin 300100,China
关键词:
复发卵巢癌症; 异环磷酰胺; 依托泊苷; 化疗
Keywords:
Key words：Recurrent ovarian cancer; Ifosfamide; Etoposide; Chemotherapy
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2019.13.044
文献标志码:
A
摘要:
目的 探讨异环磷酰胺与依托泊苷联合治疗复发卵巢癌的临床效果。方法 选取2018年1月~2019年2月我院收治的复发卵巢癌患者90例，按照随机数字表法分为对照组和观察组，各45例。对照组采用依托泊苷治疗，观察组在对照组基础上联合异环磷酰胺治疗，比较两组化疗后的效果和CA125值的变化。结果 观察组CA125、CA125Ⅱ值均低于对照组[（55.62±3.25）U/ml vs（68.42±3.25）U/ml ]、[（53.62±2.25）U/ml vs（61.42±5.25）U/ml ]，差异有统计学意义（P＜0.05）。观察组临床总有效率为95.55%，高于对照组的71.11%，差异有统计学意义（P＜0.05）。结论 异环磷酰胺与依托泊苷联合治疗复发卵巢癌可较快降低肿瘤负荷、减轻相关症状，具有较高的临床应用价值。
Abstract:
Abstract：Objective To investigate the clinical effect of combination of ifosfamide and etoposide in the treatment of recurrent ovarian cancer. Methods 90 patients with recurrent ovarian cancer admitted to our hospital from January 2018 to February 2019 were enrolled. According to the random number table, they were divided into control group and observation group, with 45 cases in each group. The control group was treated with etoposide. The observation group was given combination therapy with ifosfamide and etoposide. The effects of chemotherapy and CA125 values were compared between the two groups. Results The values of CA125 and CA125Ⅱ in the observation group were lower than those in the control group [(55.62±3.25)U/ml vs (68.42±3.25)U/ml ], [(53.62±2.25)U/ml vs (61.42±5.25)U/ml ],the difference was statistically significant (P<0.05). The total effective rate of the observation group was 95.55%, which was higher than that of the control group 71.11%,the difference was statistically significant (P<0.05).Conclusion The combination of ifosfamide and etoposide in the treatment of recurrent ovarian cancer is effective, and the recovery time is short, which has high clinical value.

参考文献/References:

[1]黄相艳.口服依托泊苷联合复方斑蝥姑息性治疗多次复发卵巢癌疗效观察[J].北方药学,2017,14(3):37-38. [2]李若玢,欧阳媛,平文萍,等.血管生成抑制剂联合化疗治疗复发性卵巢癌疗效与安全性Meta分析[J].中国实用妇科与产科杂志,2017,11(3):288-292. [3]曾庆芳,李韶今,曾红学,等.GDP化疗方案在淋巴瘤患者中的疗效观察及对生存期的影响研究[J]. 肿瘤药学,2017,7(4):488-492. [4]张富斌,崔李宁,徐科君.紫杉醇脂质体与传统紫杉醇联合卡铂治疗卵巢癌的疗效及不良反应的对比分析[J].中华全科医学,2017,15(5):808-810. [5]左立杰,刘维丽,李蕊,等.依托泊苷胶囊联合沙利度胺治疗耐药或无法耐受化疗的晚期软组织肉瘤患者的临床疗效[J].中国肿瘤临床与康复,2018,25(12):25-28. [6]杨红,张涛,杨恂,等.晚期非小细胞肺癌测定血清CA125Ⅱ水平的临床意义[J].北川医学院学报，2002,17(4):18-19.

更新日期/Last Update: 2019-07-01